Novo Nordisk Adds to Lawsuits Over 340B Discount Program

Novo Nordisk has become the latest drugmaker to file a lawsuit against HHS over 340B drug discounts, arguing that the government can’t compel it to offer discounted medications to contract pharmacies under the 340B program of Medicare.

Novo Nordisk filed its complaint on Jan. 15 in the U.S. District Court for the District of New Jersey. The firm joins AstraZeneca, Sanofi and Eli Lilly who filed separate lawsuits last week.

The drugmakers contend that the 340B drug program’s expansion to include contract pharmacies not owned by covered entity hospital creates the potential for duplicate discounts.